TP‐0903, a novel oral Axl inhibitor, has demonstrated efficacy in restraining tumor cell proliferation, metastasis, and enhancing sensitivity to chemotherapeutic agents across various solid tumors and hematological malignancies.[236, 237, 238, 239] Cabozantinib, a multireceptor tyrosine kinase inhibitor, has shown promise in preclinical trials by modulating multiple signaling pathways to impede cancer cell growth, metastasis, and neovascularization. This evidence concerns the gene AXL and hematologic disorder.